CACNA1A抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04731(CACNA1A Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04731(CACNA1A Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

The CACNA1A gene encodes the α1A subunit of voltage-gated calcium channels (Cav2.1), which are critical for neuronal excitability and synaptic transmission in the central nervous system. CACNA1A antibodies target this subunit and are associated with autoimmune neurological disorders, particularly autoimmune cerebellar ataxia, epilepsy, and encephalitis. These antibodies are often detected in patients with paraneoplastic or non-paraneoplastic syndromes, sometimes linked to underlying malignancies like ovarian or lung cancer.

Clinically, CACNA1A antibody-related disorders manifest with symptoms such as gait instability, nystagmus, dysarthria, and seizures. Diagnosis involves antibody detection via cell-based assays or immunohistochemistry, combined with clinical and imaging findings (e.g., cerebellar atrophy on MRI). The presence of these antibodies may indicate a pathogenic immune response, though their direct role in disease mechanisms—such as disrupting calcium channel function or triggering neuroinflammation—remains under investigation.

Research suggests CACNA1A antibodies may interfere with Cav2.1 channel activity, altering neurotransmitter release and neuronal signaling. Early immunotherapy (steroids, IVIG, or rituximab) often improves outcomes, highlighting the importance of timely diagnosis. However, prognostic variability exists, likely influenced by antibody titers, comorbidities, and treatment delays. Ongoing studies aim to clarify antigenic epitopes and optimize therapeutic strategies for these rare but debilitating conditions.